Document is current
Any future updates will be listed below
-
Authors
Huneault, Helaina E. https://orcid.org/0000-0003-3866-2387
Tiwari, Pradeep
Jarrell, Zachery R. https://orcid.org/0000-0003-4670-1497
Smith, Matthew Ryan https://orcid.org/0000-0002-8889-3477
Chen, Chih-Yu
Ramirez Tovar, Ana
Sanchez-Torres, Cristian
Gillespie, Scott
Bai, Shasha
Carrillo-Larco, Rodrigo M.
Jain, Ajay K.
Yates, Katherine P. https://orcid.org/0000-0001-6138-2194
Neuschwander-Tetri, Brent A. https://orcid.org/0000-0002-8520-7398
Schwimmer, Jeffrey B.
Xanthakos, Stavra A.
Molleston, Jean P.
Behling, Cynthia A.
Fishbein, Mark H.
Hartman, Terryl J.
Pasquel, Francisco J. https://orcid.org/0000-0002-3845-6703
Kamaleswaran, Rishikesan
Jones, Dean P. https://orcid.org/0000-0002-2090-0677
Welsh, Jean A.
Vos, Miriam B.
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (UL1TR002378 (MBV), UL1TR000454 (MBV), and UL1TR000448 (MBV))
- License Information
-
More Information
Article History
Received: 12 February 2025
Accepted: 28 January 2026
First Online: 24 February 2026
Competing interests
: MBV serves as a consultant to Boehringer Ingelheim, Novo Nordisk, Eli Lilly, Intercept, Takeda, and Alberio. She has stock or stock options in Thiogenesis and Tern Pharmaceuticals. Her institution has received research grants (or in-kind research services) from Target Real World Evidence, Quest, Labcorp, and Sonic Incytes Medical Corp. JPM has research grant funding from Gilead, Abbvie, Albireo, and Mirum. BANT: Advisor or consultant: Abbvie, Akero, Aldeyra, Aligos, Arrowhead, Corcept, Galectin, GSK, Hepion, HistoIndex, Madrigal, Merck, Mirum, Pfizer, Sagimet, Senseion; Stock options: HepGene, HeptaBio; Institutional research grants: Madrigal. SAX: Institutional research grants: Target Real World Evidence. The remaining authors declare no competing interests.
